{
    "nct_id": "NCT04310540",
    "official_title": "Development and Validation of Innovative Hybrid Molecular Imaging, 68Ga-PSMA-Dual Contrast PET/MRI and 68Ga-PSMA PET/CT, to Transform the Care of Patients with Hepatocellular Carcinoma",
    "inclusion_criteria": "* Patients with either an imaging diagnosis of HCC by CT or MRI (LI-RADS 5) confirmed by a board-certified abdominal radiologist, or with biopsy-proven HCC\n* Subjects who may undergo hepatic surgical resection, liver transplant, hepatic locoregional therapy (ablation, embolization, etc.) or systemic therapy\n* No prior treatment for index HCC lesion (surgical resection, liver transplant, hepatic locoregional therapy arm)\n* For the systemic therapy arm, patients who have had unequivocal progression after prior locoregional therapy (LRT) and/or those undergoing de novo systemic therapy in view of advanced HCC at diagnosis\n* Male or female with age greater than 18 years, with the capacity and willingness to provide a written informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Subjects requiring emergent surgery for a ruptured/bleeding HCC\n* Bilirubin > 3.0 mg/dL, which is a contraindication for Gadoxetate, the MRI contrast agent (relevant to PET/MRI)\n* Pregnant and/or breast-feeding subjects. A negative pregnancy test within 48 hours of the PET scan\n* Subjects with higher than the weight/size limitations of PET/MRI or PET/CT scanner\n* Subjects with contraindication to MRI (relevant to PET/MRI):\n\n  * Subjects who have a heart pacemaker\n  * Subjects who have a metallic foreign body (metal sliver) in their eye, or who have an aneurysm clip in their brain\n  * Subjects who have implanted devices with magnets\n  * Subjects who have other implanted electronic devices\n  * Subjects who have deep brain stimulator\n  * Subjects who have vagal nerve stimulator\n  * Subjects with cochlear (ear) or auditory implants",
    "miscellaneous_criteria": ""
}